Description
Emgality® (galcanezumab-gnlm) Injection 120 mg/mL – Prefilled Pen or Syringe
Product Description:
Emgality® is a prescription medication used for the preventive treatment of migraine in adults and the treatment of episodic cluster headaches. It contains galcanezumab-gnlm, a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) — a key molecule involved in migraine and cluster headache pathophysiology. Emgality helps reduce the frequency and severity of migraine attacks with convenient once-monthly dosing.
Product Features:
-
Active Ingredient: Galcanezumab-gnlm
-
Strength: 120 mg/mL
-
Dosage Form: Single-dose, subcutaneous injection
-
Presentation: Prefilled pen or prefilled syringe
-
Administration:
-
Migraine Prevention: Initial loading dose of 240 mg (2 consecutive injections), followed by 120 mg once monthly
-
Episodic Cluster Headache: 300 mg once monthly at the onset of a cluster period (administered as three 100 mg injections)
-
Reviews
There are no reviews yet.